upcoming glp-1 drugs What is the pipeline for future medications for obesity? GLP Agonist Clinical Trial Pipeline

The fact that retatrutide passed its Phase 1 and Phase 2 trials means researchers deemed it safe enough for large-scale human testing

Patients respond differently to GLP-1 medications

According to these studies, satiated rats eat more when exendin (939), a GLP- 1 receptor antagonist, is injected directly into their brains

A programme of phase 3 trials with retatrutide (TRIUMPH) is ongoing with an aim to assess the safety and efficacy of retatrutide in different populations living with obesity (OSA, T2D, established cardiovascular disease, osteoarthritis)

The Trial The ATTAIN-MAINTAIN trial enrolled patients who had achieved substantial weight loss that had plateaued while taking weekly injectable GLP-1s in the SURMOUNT-5 trial

[DOI] [PubMed] [Google Scholar] 18.Increases of the Th1/Th2 cell ratio in severe Hashimoto's disease and in the proportion of Th17 cells in intractable Graves' disease